Abstract: Methods for inhibiting an inflammatory reaction in a mammal and pharmaceutical compositions are provided. The methods comprise administering to the mammal an effective amount of a peptide of the formula: X1-X2-X3 wherein X1 is selected from the group consisting of 2-amino-hexanoic acid; 2-amino-heptanoic acid; 2-amino-octanoic acid; cyclohexyl-substituted 2-amino-ethanoic acid, 2-amino-propanoic acid or 2-amino-butanoic acid and methionine; X2 is an acidic amino acid; and X3 is an aliphatic amino acid; or of a peptide of the formula: X4-X5 wherein X4 is an aromatic or aliphatic amino acid; and X5 is an acidic amino acid.

Abstract: The invention provides a method for suppressing the development of or treating neuropathic pain in a subject comprising administering to the subject an effective amount of a peptide of the formula: X1—X2—X3 (I) or X1—X2 (II) wherein X1 is an aromatic amino acid residue or is selected from the group consisting of 2-amino-hexanoic acid, 2-amino-heptanoic acid; 2-amino-octanoic acid; cyclohexyl-substituted 2-amino-ethanoic acid, cyclohexyl-substituted 2-amino-propanoic acid or 2-amino-butanoic acid and methionine; X2 is an acidic amino acid; and in Formula (I), X3 is 1 to 3 amino acid residues which are the same or different and are aliphatic amino acid residues and the C-terminal amino acid is optionally amidated. These peptides may be used to treat a nerve injury or a spinal cord injury or to improve chronic neurological outcome after such injuries.

Abstract: Methods for inhibiting an inflammatory reaction in a mammal and pharmaceutical compositions are provided. The methods comprise administering to the mammal an effective amount of a peptide of the formula: X1-X2-X3 wherein X1 is selected from the group consisting of 2-amino-hexanoic acid; 2-amino-heptanoic acid; 2-amino-octanoic acid; cyclohexyl-substituted 2-amino-ethanoic acid, 2-amino-propanoic acid or 2-amino-butanoic acid and methionine; X2 is an acidic amino acid; and X3 is an aliphatic amino acid; or of a peptide of the formula: X4-X5 wherein X4 is an aromatic or aliphatic amino acid; and X5 is an acidic amino acid.

Abstract: Methods for inhibiting an inflammatory reaction in a mammal and pharmaceutical compositions are provided. The methods comprise administering to the mammal an effective amount of a peptide of the formula: X1-X2-X3 wherein X1 is selected from the group consisting of 2-amino-hexanoic acid; 2-amino-heptanoic acid; 2-amino-octanoic acid; cyclohexyl-substituted 2-amino-ethanoic acid, 2-amino-propanoic acid or 2-amino-butanoic acid and methionine; X2 is an acidic amino acid; and X3 is an aliphatic amino acid; or of a peptide of the formula: X4-X5 wherein X4 is an aromatic or aliphatic amino acid; and X5 is an acidic amino acid.

Abstract: Submandibular peptides have been isolated and characterised and provide pharmaceutical compositions for the treatment or prevention of anaphylactic reactions, endotoxic reactions and SIRS-induced shock.

Abstract: Submandibular peptides have been isolated and characterized and provide pharmaceutical compositions for the treatment or prevention of anaphylactic reactions, endotoxic reactions and SIRS-induced shock.

Abstract: Submandibular peptides have been isolated and characterised and provide pharmaceutical compositions for the treatment or prevention of anaphylactic reactions, endotoxic reactions and SIRS-induced shock.

Abstract: Methods for inhibiting an inflammatory reaction in a mammal and pharmaceutical compositions are provided.

Abstract: This invention relates to methods and compositions of tripeptides and dipeptides having anti-inflammatory activities that can be used for the treatment of allergic and inflammatory reactions. A peptide of the formula: X-R.sub. 1 -R.sub.2 -R.sub.3 -Y  (I) or X-R.sub. 1 -R.sub.2 -Y  (II) wherein X is selected from the group consisting of H and acetyl; R.sub. 1 is selected from the group consisting of D or L-phenylalanine; tyrosine; tryptophan; phenylglycine; Nor-methylphenylalanine; cyclohexylalanine; and norleucine; R.sub.2 is selected from the group consisting of D or L-glutamate; and aspartate; and in the case of peptide (II), R.sub.3 is selected from the group consisting of glycine; D or L-alanine; beta-alanine; valine; leucine; isoleucine; sarcosine; and gamma-aminobutyric acid or another aliphatic amino acid; and Y is selected from the group consisting of OH and NH.sub.2, but excluding the dipeptides H-L-Phe-L-Glu-OH, H-L-Trp-L-Glu-OH, H-D-Phe-D-Glu-OH and H-D-Trp-D-Glu-OH.